210 related articles for article (PubMed ID: 12517808)
1. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
2. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Nowak-Göttl U; Heinecke A; von Kries R; Nürnberger W; Münchow N; Junker R
Thromb Res; 2001 Aug; 103(3):165-72. PubMed ID: 11672578
[TBL] [Abstract][Full Text] [Related]
4. [Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
Janić D; Dokmanović L; Jovanović N; Skorić D; Lazić J
Srp Arh Celok Lek; 2004 Oct; 132 Suppl 1():17-22. PubMed ID: 15615459
[TBL] [Abstract][Full Text] [Related]
5. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
6. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
7. [Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols].
Sutor AH; Niemeyer C; Sauter S; Witt I; Kaufmehl K; Rombach A; Brandis M; Riehm H
Klin Padiatr; 1992; 204(4):264-73. PubMed ID: 1518263
[TBL] [Abstract][Full Text] [Related]
8. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Risk Factors for Hypertension During Childhood Acute Lymphoblastic Leukemia Therapy.
Malhotra P; Kapoor G; Jain S; Garg B
Indian Pediatr; 2018 Oct; 55(10):877-879. PubMed ID: 29941701
[TBL] [Abstract][Full Text] [Related]
10. Inherited prothrombotic risk factors in Turkish children with acute lymphoblastic leukemia: significance of concomitant genetic mutation.
Torun YA; Patiroglu T; Ozdemir MA; Ozkul Y; Ekici A; Karakukcu M
Clin Appl Thromb Hemost; 2012; 18(2):218-21. PubMed ID: 21873357
[TBL] [Abstract][Full Text] [Related]
11. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Appel IM; Hop WC; Pieters R
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
[TBL] [Abstract][Full Text] [Related]
12. PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.
Szarzyńska-Zawadzka B; Kunz JB; Sędek Ł; Kosmalska M; Zdon K; Biecek P; Bandapalli OR; Kraszewska-Hamilton M; Jaksik R; Drobna M; Kowalczyk JR; Szczepański T; Van Vlierberghe P; Kulozik AE; Witt M; Dawidowska M
Am J Hematol; 2019 Apr; 94(4):E93-E96. PubMed ID: 30614545
[No Abstract] [Full Text] [Related]
13. No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
Felice MS; Rossi JG; Gallego MS; Alfaro EM; Zubizarreta PA; Fraquelli LE; Alonso CN; Guitter MR; Scopinaro MJ
Pediatr Blood Cancer; 2011 Jul; 57(1):47-55. PubMed ID: 21394895
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
[No Abstract] [Full Text] [Related]
16. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
[TBL] [Abstract][Full Text] [Related]
17. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
Zdráhalová K; Štěrba J; Domanský J; Blažek B; Ptoszková H; Mihál V; Novák Z; Hak J; Procházková D; Černá Z; Timr P; Jabali Y; Sedláček P; Smíšek P; Zemanová Z; Jarošová M; Houdková A; Mejstříková E; Hrušák O; Zuna J; Janotová I; Trka J; Starý J
Cas Lek Cesk; 2015; 154(2):79-89. PubMed ID: 25994910
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
Yamamoto M; Hori T; Igarashi K; Iesato K; Saito M; Miyanishi K; Kikuchi N; Fujita H; Tsutsumi H
Int J Hematol; 2018 Apr; 107(4):390-391. PubMed ID: 29181701
[No Abstract] [Full Text] [Related]
19. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Holownia A; Trofimiuk E; Krawczuk-Rybak M; Jakubow P; Kaliszewski J; Muszynska-Roslan K; Braszko JJ
Acta Haematol; 2004; 112(4):222-4. PubMed ID: 15564737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
